Minimal sufficient balance—a new strategy to balance baseline covariates and preserve randomness of treatment allocation
暂无分享,去创建一个
[1] Wenle Zhao,et al. Quantitative comparison of randomization designs in sequential clinical trials based on treatment balance and allocation randomness , 2012, Pharmaceutical statistics.
[2] Gerd K Rosenkranz,et al. The impact of randomization on the analysis of clinical trials , 2011, Statistics in medicine.
[3] Wenle Zhao,et al. Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization. , 2011, Contemporary clinical trials.
[4] Vance W Berger,et al. Minimization, by its nature, precludes allocation concealment, and invites selection bias. , 2010, Contemporary clinical trials.
[5] T. Kent,et al. A Matching Algorithm to Address Imbalances in Study Populations: Application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator Acute Stroke Trial , 2010, Stroke.
[6] Stephen Senn,et al. Comparisons of minimization and Atkinson's algorithm , 2010, Statistics in medicine.
[7] Andrea Manca,et al. A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. , 2010, Journal of clinical epidemiology.
[8] L. Hothorn. Statistical issues in drug development (2nd edn). Stephen Senn, John Wiley & Sons Ltd, Chichester, 2007. No. of pages: xix + 498. Price: $130.00. ISBN 978‐0‐470‐01877‐4 , 2009 .
[9] P. Fayers,et al. In reply to Berger “don’t test for baseline imbalances unless they are known to be present?” , 2009, Quality of Life Research.
[10] P. Bath,et al. Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? , 2009, Stroke.
[11] Nimodipine BI Orgo,et al. Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors ? , 2009 .
[12] J. Burton,et al. A User's Guide to the NINDS rt-PA Stroke Trial Database , 2008, PLoS medicine.
[13] J. Saver,et al. Confirmation of tPA Treatment Effect by Baseline Severity-Adjusted End Point Reanalysis of the NINDS-tPA Stroke Trials , 2007, Stroke.
[14] E. Steyerberg,et al. Adjustment for strong predictors of outcome in traumatic brain injury trials: 25% reduction in sample size requirements in the IMPACT study. , 2006, Journal of neurotrauma.
[15] V. Berger. Selection Bias and Covariate Imbalances in Randomized Clinical Trials: Berger/Selection Bias and Covariate Imbalances in Randomized Clinical Trials , 2005 .
[16] J. Mann. NINDS Reanalysis Committee's reanalysis of the NINDS trial. , 2005, Stroke.
[17] T. Louis,et al. Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial , 2004, Stroke.
[18] Anastasia Ivanova,et al. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures , 2003, Statistics in medicine.
[19] J. Matthews,et al. Randomization in Clinical Trials: Theory and Practice; , 2003 .
[20] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[21] S. Black,et al. tPA for acute stroke: balancing baseline imbalances , 2002 .
[22] L. Kuller,et al. National guidelines, clinical trials, and quality of evidence. , 2000, Archives of internal medicine.
[23] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[24] A. Atkinson,et al. Optimum biased-coin designs for sequential treatment allocation with covariate information. , 1999, Statistics in medicine.
[25] R. Peto. Failure of randomisation by “sealed” envelope , 1999, The Lancet.
[26] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[27] Stephen Senn,et al. Statistical Issues in Drug Development , 1997 .
[28] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[29] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[30] S. Senn. Testing for baseline balance in clinical trials. , 1994, Statistics in medicine.
[31] D. G. Altman,et al. Randomisation and baseline comparisons in clinical trials , 1990, The Lancet.
[32] S J Senn,et al. Covariate imbalance and random allocation in clinical trials. , 1989, Statistics in medicine.
[33] C. F. Wu,et al. Some Restricted randomization rules in sequential designs , 1983 .
[34] A. Atkinson. Optimum biased coin designs for sequential clinical trials with prognostic factors , 1982 .
[35] D. DeMets,et al. Fundamentals of Clinical Trials , 1982 .
[36] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[37] D R Taves,et al. Minimization: A new method of assigning patients to treatment and control groups , 1974, Clinical pharmacology and therapeutics.